The FDA approved Moderna's new COVID-19 vaccine, mNexspike, for adults 65+ and those 12-64 with high-risk health conditions. This lower-dose vaccine is an alternative to Moderna's existing shot, Spikevax, and offers similar or improved efficacy. The approval comes with usage restrictions, unlike Moderna's original vaccine, a shift potentially influenced by vaccine skepticism. Moderna plans to offer both vaccines this fall.

Prepared by Olivia Bennett and reviewed by editorial team.